Phaseline

Targets › EHMT2

EHMT2 (Histone-lysine N-methyltransferase EHMT2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.

Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. (UniProt, Q96KQ7)

Open in Phaseline: the race on EHMT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universityzemetostat
G9a/GLP histone methyltransferase inhibitor
EHMT2Phase 2Soft Tissue SarcomaNov 2028

Conditions

Soft Tissue Sarcoma (1)

Modalities

small molecule (1)

Companies

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.